검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Steroids |
Overview Company | Bausch & Lomb Incorporated |
Overview Modality | ANTIBODY |
Overview Target | End Stage Renal Disease |
Overview Indication | Crohn's Disease; IBD |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | target modulation of cAMP‑PI3K/Akt-GSK‑3β and NF‑κB signaling |
MoA Biomarker | biomarker for disease diagnosis |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Pembrolizumab-induced severe eczematous dermatitis and the use of methotrexate as a steroid-sparing agent.. Immune checkpoint inhibitors, a first-line treatment of metastatic melanoma and other cancers, improve survival but commonly cause immune-related cutaneous adverse events. Early recognition and classification of these adverse events are important for effective management. We present a case o… |
Clinical Primary efficacy | ORR 77.8% |
Clinical ORR | 77.8% |
Clinical Result source | ClinicalTrials.gov NCT02020941 |
Clinical Data Tier / Score | A · 57 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Steroids |
Overview Company | Bausch & Lomb Incorporated |
Overview Modality | ANTIBODY |
Overview Target | End Stage Renal Disease |
Overview Indication | Crohn's Disease; IBD |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | target modulation of cAMP‑PI3K/Akt-GSK‑3β and NF‑κB signaling |
MoA Biomarker | biomarker for disease diagnosis |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Pembrolizumab-induced severe eczematous dermatitis and the use of methotrexate as a steroid-sparing agent.. Immune checkpoint inhibitors, a first-line treatment of metastatic melanoma and other cancers, improve survival but commonly cause immune-related cutaneous adverse events. Early recognition and classification of these adverse events are important for effective management. We present a case o… |
Clinical Primary efficacy | ORR 77.8% |
Clinical ORR | 77.8% |
Clinical Result source | ClinicalTrials.gov NCT02020941 |
Clinical Data Tier / Score | A · 57 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교